SCHEMBL19325599

SCHEMBL19325599

CC1(C)CCc2c(sc(-c3ccccc3CON)c2C(=O)O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.39
PDE4D Q08499 1/20 0.39
RAB7A P51149 1/20 0.39
SLC34A2 O95436 2/20 0.39
CACNA1G O43497 7/20 0.38
CACNA1H O95180 7/20 0.38
CACNA1I Q9P0X4 7/20 0.38
KIF11 P52732 1/20 0.38
FABP4 P15090 2/20 0.36
FABP5 Q01469 2/20 0.36
KCNH2 Q12809 1/20 0.34
CACNA1C Q13936 1/20 0.34
ALDH1A1 P00352 3/20 0.32
HPGD P15428 2/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19325531 0.92 RAB7A (0.46) PDE4BPDE4DRAB7ASLC34A2CACNA1G
SCHEMBL19320875 0.91 CACNA1G (0.47) PDE4BPDE4DRAB7ASLC34A2CACNA1G
SCHEMBL19326200 0.88 CNR2 (0.41) FABP4FABP5HPGDCNR1CNR2
SCHEMBL19326182 0.83 RAB7A (0.41) RAB7ASLC34A2CACNA1GCACNA1HCACNA1I
SCHEMBL19325792 0.82 MAPT (0.44) ALDH1A1HPGDSMN1; SMN2LMNAHTT
SCHEMBL19320826 0.82 CACNA1G (0.47) RAB7ASLC34A2CACNA1GCACNA1HCACNA1I
SCHEMBL19325604 0.81 MEN1 (0.46) ALDH1A1HPGDSMN1; SMN2LMNAHTT
SCHEMBL19325607 0.81 MEN1 (0.46) ALDH1A1HPGDSMN1; SMN2LMNAHTT
SCHEMBL19326147 0.81 CNR2 (0.34) RAB7ACNR1CNR2
SCHEMBL19325537 0.81 CNR2 (0.36) RAB7ACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR SHIONOGI & CO., LTD. (JP) 2017-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR CPN1, HAT1, PRSS1 PDE4B 4744/4885PDE4D 4818/4885RAB7A 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.